The Efficacy of Adjuvant Endocrine Therapy for ER(-)PR(+) Primary Breast Cancer

YU Ke-da,DI Gen-hong,WU Jiong,LU Jin-song,SHEN Kun-wei,SHEN Zhen-zhou,SHAO Zhi-min

DOI: https://doi.org/10.3969/j.issn.1007-3639.2006.12.005

2006-01-01

Abstract:Background and purpose:Progesterone receptor(PR) status provides predictive value for adjuvant endocrine therapy in estrogen receptor(ER)-positive breast cancer patients.It is recommended for the patients with both ER and PR positive to receive adjuvant hormone therapy.However,it still is a controversial issue how much efficacy of adjuvant endocrine therapy is for ER(-)PR(+) tumors.This study was to investigate the options of adjuvant endocrine therapy for ER(+)PR(+) primary breast cancer(205 cases) and ER(-)PR(+) primary breast cancer(798 cases).Methods:The expressions of ER and PR status in 1836 consecutive operable patients of primary breast cancer were treated into Shanghai Cancer Hospital between Jan 1991 and Dec 2001 and reviewed.The differences of DFS and OS for ER(-)PR(+) group and ER(+)PR(+) group with or without endocrine therapy were analyzed with median following period up to 48 months(6-141 months).The survival time were calculated by Kaplan-Meier and 5-year survival rates were evaluated by Life Table estimates.Results:ER(-)PR(+) patients accounted for 11.0% of the whole population,and median age was 49 years.The proportion of premenopausal patients was higher in ER(-)PR(+) group(63.9%) compared to ER(+)PR(+) group,the ER(-)PR(+) group had also more auxiliary lymph node metastases,larger mass and higher clinical staging than that in ER(+)PR(+) group.The DFS and OS were similar between both groups in the absence of endocrine therapy,however,the ER(+)PR(+) group had a significant better survival than ER(-)PR(+) group if hormonal treatment was added into the treatment(DFS:P=0.016,OS:P=0.007),and both groups had better 5-year survival after the treatment of hormonal therapy.The 5-year DFS rate increased from 68.7% to 79.0% in ER(+)PR(+) group,and from 56.6% to 70.9% in ER(-)PR(+) group;similar results were found in OS.The multivariate analysis showed that the status of auxiliary lymph node metastases was only important independent prognostic factor for ER(-)PR(+) patients.Conclusions:The adjuvant endocrine therapy is more effective for ER(+)PR(+) primary breast cancer than for ER(-)PR(+) primary breast cancer.Further study is needed determined the best option of hormone therapy for the patients with ER(-)PR(+) status.